In this article, we review the traditional therapies of hereditary angioedema (HAE) that have been used for several years. Some of these therapies were proposed before the definition of the underlying defect and the understanding of the pathogenesis of the disease. We also describe new compounds under investigation at present as potential therapies for HAE. Two of these new therapies (a plasma-kallikrein inhibitor and a bradykinin B(2)-receptor antagonist) have been developed based on the understanding that the pathogenesis of symptoms was mainly due to kallikrein activation and bradykinin release. (c) 2007 Elsevier GmbH. All rights reserved.
The deficiency of C1 inhibitor and its treatment / M. Cicardi, L.C. Zingale. - In: IMMUNOBIOLOGY. - ISSN 0171-2985. - 212:4-5(2007), pp. 325-331. [10.1016/j.imbio.2007.04.003]
The deficiency of C1 inhibitor and its treatment
M. CicardiPrimo
;L.C. ZingaleUltimo
2007
Abstract
In this article, we review the traditional therapies of hereditary angioedema (HAE) that have been used for several years. Some of these therapies were proposed before the definition of the underlying defect and the understanding of the pathogenesis of the disease. We also describe new compounds under investigation at present as potential therapies for HAE. Two of these new therapies (a plasma-kallikrein inhibitor and a bradykinin B(2)-receptor antagonist) have been developed based on the understanding that the pathogenesis of symptoms was mainly due to kallikrein activation and bradykinin release. (c) 2007 Elsevier GmbH. All rights reserved.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
